What is Centrose?
Centrose operates at the intersection of molecular biology and precision medicine, specializing in the development of next-generation antibody-drug conjugates, specifically termed Extracellular Drug Conjugates (EDCs). Unlike traditional internalizing conjugates, the Centrose platform targets the cell surfaceome, enabling the binding of multiple extracellular proteins without the requirement for internalization. This innovative mechanism is engineered to significantly enhance the potency and safety profiles of cancer therapies. The company is currently prioritizing the treatment of drug-resistant non-Hodgkin lymphoma and various metastatic cancers, aiming to redefine standard-of-care protocols through its highly selective therapeutic delivery systems.
How much funding has Centrose raised?
Centrose has raised a total of $4M across 3 funding rounds:
Debt
$500K
Debt
$2M
Private Equity
$1.4M
Debt (2010): $500K, investors not publicly disclosed
Debt (2013): $2M, investors not publicly disclosed
Private Equity (2015): $1.5M, investors not publicly disclosed
Key Investors in Centrose
Undisclosed Investor
An institutional capital provider specializing in late-stage private equity and enterprise-level growth financing for high-impact biotechnology firms.
Undisclosed Investor
A specialized credit firm focused on providing structured debt solutions to support the operational scaling of innovative life sciences companies.
Undisclosed Investor
A financial institution dedicated to providing non-dilutive capital to emerging biotech enterprises during critical development milestones.
What's next for Centrose?
With the recent influx of capital, Centrose is well-positioned to accelerate its clinical pipeline and expand its therapeutic target list. The strategic focus will likely shift toward scaling manufacturing capabilities and initiating advanced-phase trials to validate the efficacy of its EDCs in broader patient populations. As the company navigates the complexities of the oncology market, the emphasis will remain on optimizing the safety-to-potency ratio of its drug candidates. Future growth will be contingent upon the successful translation of its surfaceome-targeting technology into clinical outcomes, potentially positioning Centrose as a key player in the next wave of targeted cancer therapeutics. Keywords: Centrose, Biotechnology, Antibody-Drug Conjugates, EDCs, Oncology, Precision Medicine, Clinical Development, Cancer Therapeutics.
See full Centrose company page
